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ABSTRACT
Aims: The American College of Cardiology (ACA)/ American Heart Association (AHA) granted Galectin-3 (Gal-3) and Suppression of Tumorigenicity 2 (ST2) 
evaluation a class II recommendation for HF prognosis, as an adjunctive to conventional clinical risk factors and natriuretic peptides dosing in 2013. 
However, in Europe this endorsement is not valid. The purpose of this study was to study the association of Gal-3 and ST2 collected at-admission with 
early (defined as the period of 90 days post-discharge) rehospitalization and overall mortality, and end of follow-up overall mortality in HF patients. Addi-
tionally, aminoterminal B-type natriuretic peptide (NT-proBNP) at admission was considered to test if a multi-marker strategy could yield supplementary 
information.
Material and Methods: Gal-3, ST2 and NT-proBNP were assessed in patients hospitalized with acute decompensated HF in class III or IV of New York 
Heart Association (NYHA). Univariate Cox proportional hazard model was used to assess the relationship between variables and outcomes. Since there are 
no standardized cut-offs for Gal-3 and ST2, the multiclass Area Under the Curve Receiver-Operator Characteristic (AUCROC) as defined by Hand and Till 
was used to evaluate the overall performance of each biomarker as a predictor of the outcomes.
Results: We followed 65 patients for a median of 13.7 (Q1-Q3 6.7-18.9) months. Gal-3 correlated with short-term rehospitalization (HR: 9.886, 95% CI: 
2.027-48.214, P-value=0.005), short-term mortality (HR: 13.731, 95% CI: 1.650-114.276, P value=0.015) and end of follow-up mortality (HR: 4.492, 
95% CI: 1.594-12.656, P-value=0.004). The association of elevated NT-proBNP determinations increased the risk of short-term rehospitalization (HR: 
11.985, 95% CI: 1.962-73.218, P value=0.007) and end of follow-up mortality (HR: 78.025, 95% CI: 7.592-801.926, P-value<0.001). ST2 correlated 
with end of follow-up mortality (HR: 4.846, 95% CI: 1.396-16.825, P-value=0.013). The risk further increased if NT-proBNP (HR: 5.953, 95% CI: 1.683-
21.055, P-value=0.006) or Gal-3 determinations (HR: 6.209, 95% CI: 2.393-16.114, P-value<0.001) were added.
Conclusions: Elevated Gal-3 concentrations correlated with short-term rehospitalization, short-term mortality and end of follow-up mortality; whereas 
ST2 prognosticated end of follow-up mortality.  Collective analysis with elevated NT-proBNP values further increased the outcomes’ risk. These results 
corroborate the assumption that promising novel biomarkers Gal-3 and ST2 could be valuable for HF risk stratification. We highlight that a multi-marker 
strategy added information, as a synergism between myocardial fibrosis biomarkers and the myocardial stretch peptide was observed.
Key Words: Acute decompensated heart failure; Short-term readmission; Short-term mortality; Galectin-3; ST2; NT-proBNP. 
INTRODUCTION
Despite scientific advances HF short-term prognosis re-
mains poor, as circa 25% of patients are readmitted in the 
first 30 days after hospital discharge1 and approximately 
30% are readmitted 60 to 90 days post-discharge2.
Remarkably, the mortality rate 60 to 90 day post-discharge 
reaches 15%1.
It urges to define a short-term prognosis for HF patients in 
order to reduce readmission and premature mortality.
The actual treatment paradigm of HF is based, fundamen-
tally, on the blockade of the renin-angiotensin-aldosterone 
system, nevertheless other mechanisms influence the gen-
esis and progression of this syndrome.
The need for risk markers in precocious stages of the dis-
ease, in order to refrain its evolution, has led to an increas-
ing interest in biomarkers related to the physiopathological 
pathways of HF, namely myocardial fibrosis. Myocardial 
fibrosis seems to favor left ventricular dysfunction which 
determines HF progression3.
Clinical judgement, the cornerstone of medical praxis is 
enhanced by imaging and biological diagnostic tests. 
Fibrosis biomarkers emerge as promising tools that can 
complement traditional clinical practice by recognizing 
high risk patients that could benefit from therapeutic inten-
sification and stricter surveillance.
The role of natriuretic peptides as diagnostic predictors is 
undisputed,4 but Gal-35, 6 and ST27, 8 seem to be superior 
concerning prognosis. 
In 2013, the ACA/ AHA recognized ST2 and Gal-3 as HF 
prognosticators,9 nevertheless the European Society of 
Cardiology (ESC) does not support this recommendation10. 
Interestingly, a multi-marker strategy appears to yield ad-
ditional information, as current data alludes a synergism 
between myocardial stretch peptides and fibrosis biomark-
ers4, 5, 6, 11.
MATERIAL AND METHODS 
Study design and population
The pREdictors oF Early REadmission iN Chronic hEart failure 
(REFERENCE) was an observational prospective cohort, sin-
gle-center, single-arm study.
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a Patients were recruited consecutively for a period of 12 
months from an Internal Medicine ward.
Inclusion criteria were age ≥18 years old and hospitalization 
due to chronic decompensated HF patients in class III or IV 
of NYHA.
Exclusion criteria were:
1. in-hospital death in the first hospitalization; 
2. hospital discharge against medical advice; 
3. chronic kidney disease patients with a glomerular filtra-
tion rate (GRF) <30 ml/min/1.73 m2 (calculated with the 
Modification of Diet in Renal Disease score) or under re-
nal replacement therapy; 
4. moderate or severe hepatic impairment (calculated with 
the Child-Pugh score); 
5. active neoplasm with or without metastasis. 
The participation in the study was entirely voluntary and all 
eligible subjects signed the written informed consent.
The study was performed in conformity with its protocol, the 
Declaration of Helsinki and the Oviedo Convention. The study 
was approved by an Institutional Review Board (Academic 
Medical Center Ethics Committee). 
Protocol and definitions
The diagnosis of HF was based on the ESC guidelines10.
Patient evaluation followed study protocol that included clini-
cal history, physical examination, 12-lead electrocardiogram, 
thoracic X-ray, blood sampling for laboratory tests, transtho-
racic Doppler echocardiography and therapeutic data.
All echocardiograms M mode, two-dimensional and Doppler 
were performed by an experienced operator using a Hitachi 
Aloka alfa 6 Medical device with a 2.5 MHz transducer.
Biochemical parameters were assessed as per routine using 
plasma samples. 
Biomarkers were measured using plasma samples. 
Plasma samples were stored at the study sites at -20ºC, 
followed by storage at -80ºC. 
Galectin-3 and ST2/IL-33R were quantified in plasma using 
pre-coated human ELISA R&D Systems, Abingdon, USA kits. 
Plasma NT-proBNP values were measured using electroche-
miluminescence immunoassay Elecsys NT-proBNP Roche 
Diagnostics, GmbH, Mannheim, Germany. 
In light of the European Society of Cardiology guidelines, HF 
with preserved ejection fraction (HFpEF) was defined as left 
ventricular ejection fraction (LVEF) ≥ 50%, midrange ejection 
fraction (HFmrEF) was defined as LVEF 40-49% and reduced 
ejection fraction (HFrEF) was defined as LVEF < 40%.10
Outcomes
We studied the correlation of Gal-3 and ST2 with short-term 
rehospitalization due to HF, short-term all-cause mortality 
and end of follow-up all-cause mortality in HF patients. 
Short-term rehospitalization was defined as rehospitalization 
within 90 days of hospital discharge. 
Short-term mortality was defined as death occurring within 
90 days after hospital discharge.
End of follow-up mortality was defined as death that oc-
curred during the entire study period.
Statistical analysis
Convenience sampling was used and no sample size cal-
culation was performed. Categorical variables were sum-
marized by relative and absolute frequencies and compared 
using the chi-squared test or Fisher’s Exact test. 
Continuous variables were summarized by mean, standard 
deviation, median, first and third quartiles (Q1-Q3). Shap-
iro-Wilk test was used to assess the normality of continuous 
variables. Comparisons between patients with or without an 
event of interest were performed using the t-test or Wilcoxon 
Rank test, as applicable. 
Short-term rehospitalization, short-term mortality and end 
of follow-up mortality were considered as stratification vari-
ables.
A survival analysis was performed for the events of interest.
For each endpoint, Kaplan-Meier survival estimates were 
calculated and plotted for each categorical variable. Log-
rank tests were used to compare survival probabilities in 
each of the considered variables. A univariate Cox propor-
tional hazards model was fitted to the data to obtain HR and 
95% CI for each variable. 
The proportional hazards assumption was tested using 
Schoenfeld residuals. All analyses were conducted at an 
overall significance level of 5%. No imputation was per-
formed on missing data. No adjustments for multiplicity were 
performed. 
Since there are no standardized cut-offs for Gal-3 and ST2, 
the multiclass AUCROC as defined by Hand and Till was used 
to evaluate the overall performance of each biomarker as a 
predictor of the outcomes.
Taking into consideration the low number of subjects, it was 
decided to consider as relevant predictors biomarkers that 
had an AUCROC above 0.7 and in which the 95% confidence 
interval did not contain 0.5 (value for which the predictor 
makes random guesses). The optimal cut-off value for each 
biomarker to predict each of the events was defined using 
the Youden Index, which maximizes the sensitivity and spec-
ificity of the predictor. Negative predictive values (NPV) and 
positive predictive values (PPV) were calculated and reported 
for the selected cut-offs.
RESULTS
From the 70 selected patients 5 were excluded from the 
analysis given that during follow-up they were diagnosed 
with active neoplasm.
The 65 patients who matched the selection criteria had a 














The mean age of the patients was 79.2 ± 10.8 years, 56.9% 
were female and their mean LVEF was 50.38 ± 19.07 %.
Baseline characteristics of the population study are present-
ed in Table 1. 
The 90-day post-discharge readmission percentage was 
33.8% and the 90-day mortality was 18.5%. By the end of 
follow-up 40% of the patients had died. 
Spearman’s correlation coefficient
Spearman’s correlation coefficient recognized an inversely 
proportional correlation between Gal-3 levels and baseline 
glomerular filtration rate (GFR) (Coefficient: -0.537, P-val-
ue<0.001) and admission GFR (Coefficient: -0.549, P-val-
ue<0.001). 
In contrast, Spearman’s correlation revealed that Gal-3 and 
NT-proBNP values were proportional (Coefficient: 0.383, 
P-value=0.009), as depicted in Figure 1.
The same statistical method showed a significant negative 
correlation between ST2 levels and baseline GFR (Coeffi-
cient: -0.418, P-value<0.001) and admission GFR (Coeffi-
cient: -0.438, P-value<0.001). 
ROC analysis
Regarding ROC analysis, for the short-term rehospitalization 
outcome, only Gal-3 had an acceptable AUCROC value (AU-
CROC: 0.74; CI95%: 0.55-0.92). For this biomarker, the opti-
mal cut-off value (Youden Index) was 11.41 ng/mL with a high 
NPV (0.93) indicating a good capability in predicting (93% 
probability) that no short-term rehospitalization events occur 
if the biomarker is below the cut-off. The PPV was 0.54, being 
able to predict the event with a probability of 54%.
Concerning the short-term mortality outcome, there were two 
biomarkers with acceptable AUCROC values, Gal-3 (AUCROC: 
0.85; CI95%: 0.74-0.97) and NT-proBNP (AUCROC: 0.75; 
CI95%: 0.58-0.92).
For Gal-3, the optimal cut-off value was 10.98 ng/mL with a 
perfect NPV (1.0), indicating an excellent capability in predicting 
(100% probability) that no short-term mortality events occur 
if the biomarker is below the cut-off. Regarding the capability 
of predicting short-term mortality events, the biomarker had 
inferior capabilities (PPV: 0.44), but it is still relevant enough 
to take it into consideration, given the 44% probability of the 
event to occur. 
For NT-proBNP the optimal cut-off value was 21336 ng/L with 
a high NPV (0.91). The PPV was inferior (0.64), being able to 
predict with 64% probability an event of short-term death.
Minding the end of follow-up mortality outcome, we decided 
to consider Gal-3 and ST2 although they had an AUCROC 
slightly below 0.7 [Galectin-3 (AUCROC: 0.69; CI95%: 0.52-
0.86) and ST2 (AUCROC: 0.69; CI95%: 0.53-0.85)], due to 
the fact that they had a significant behavior (95% confidence 
intervals above 0.5).
For Gal-3 the optimal cut-off value was 9.99 ng/mL with a 
NPV of 0.78 and PPV of 0.65. 
The ST2 biomarker had similar capabilities to Gal-3, with an 
optimal cut-off value of 24.79 ng/Lwith NPV of 0.83 and a 
PPV of 0.60. 
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Figure 1. Spearman correlation of Galectin-3 and NT-proBNP 
 
(r= 0.383, P-value=0.009)
Figure 2. Short-term mortality - Kaplan Meier: GAL3 ≥10.97 ng/mL
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We acknowledged that Gal-3 ≥11.41 ng/mL correlated with 
short-term rehospitalization (HR: 11.762, 95% CI: 2.402-
57.598, P-value=0.002). 
A link between Gal-3 ≥10.97 ng/mL and short-term mortal-
ity (HR: 13.731, 95% CI: 1.650-114.276, P value=0.015, 
Figure 2) and end of follow-up mortality (HR: 3.418, 95% CI: 
1.345-8.689, P-value=0.010) was also identified. 
The association of NT-proBNP ≥21336 ng/L with Gal-3 
≥10.97 further increased the risk of short-term rehospital-
ization (HR: 11.985, 95% CI: 1.962-73.218, P value=0.007) 
and end of follow-up mortality (HR: 78.025, 95% CI: 7.592-
801.926, P-value<0.001), as shown in Table 2.
A correlation between ST2 ≥24.78 ng/L and end of fol-
low-up mortality was acknowledged (HR: 4.846, 95% CI: 
1.396-16.825, P-value=0.013, Table 3). 
If values of NT-proBNP ≥21336 ng/L were added to levels 
of ST2 ≥24.78 ng/L the risk augmented up to 6 times (HR: 
Table 1. Baseline characteristics of the population study
Characteristics Patients (n=65)
Age, mean (SD) 79.2 ± 10.8
Female Gender, n (%) 37 (56.9)
Hypertension, n (%) 58 (89.2)
Type 2 Diabetes, n (%) 25 (38.5)
Dyslipidemia, n (%) 41 (63.1)
Obesity, n (%) 17 (26.2)
Atrial Fibrillation, n (%) 28 (43.1)
Family History of CVD, n (%) 31 (47.7)
Tabagism, n (%) 21 (32.3)
Chronic Kidney Disease, n (%) 34 (52.3)
GFR (Baseline), median 57.8 (43.8 - 82.2)
GFR (Admission), median 47.9 (33.2 - 68.1)
Previous Acute Myocardial Infarction, n (%) 27 (41.5)
Hypertensive Heart disease, n (%) 44 (67.7)
Ischemic Heart disease, n (%) 22 (33.8)
Valvular Heart disease, n (%) 56 (86.2)
LVEF, mean (SD) 50.38 ± 19.07
NYHA class III, n (%) 43 (66.2)
ACE Inhibitor, n (%) 43 (66.2)
Beta Blocker, n (%) 38 (58.5)
Mineralocorticoid Receptor Antagonists, n (%) 19 (29.2)
Angiotensin II Receptor Blocker, n (%) 11 (16.9)
Loop Diuretic, n (%) 54 (83.1)
Digoxin, n (%) 8 (12.3)
Galectin-3, median 9.82 (7.94 -12.00)
ST2, median 27.22 (15.45-44.39)
NT-proBNP (Admission), median 5701.0 (1867 - 11961)
Values are median (IQR), n (%), or mean ± SD. 
IQR: interquartile range and minimum/maximum, SD: standard deviation, CVD: cardiovascular disease,  
GFR: glomerular filtration rate, ACE: Angiotensin-Converting-Enzyme.
5.953, 95% CI: 1.683-21.055, P-value=0.006) and if, in-
stead, values of Gal-3 ≥9.99 ng/mL were considered the 
risk increased roughly to the same extent (HR: 6.209, 95% 
CI: 2.393-16.114, P-value<0.001, Table 3). 
For the HFrEF subgroup the end of follow-up mortality risk 
for the combined values of ST2 ≥24.78 ng/L and Gal-3 
≥9.99 ng/mL was highest (HR: 15.782, 95% CI: 1.593-
156.322, P-value=0.018) compared to the general popu-
lation (HR: 6.209, 95% CI: 2.393-16.114, P-value<0.001) 
and the HFpEF subgroup (HR: 5.2, 95% CI: 1.223-22.187, 
P-value=0.026, Table 3).
DISCUSSION
Gal-3 is a soluble β-galactoside-binding protein which is 
produced by activated macrophages. It plays a pivotal role in 
cardiac fibroblast proliferation and collagen synthesis which 
result in left ventricular stiffness and ultimately in ventricular 
dysfunction. 12
Although this acute and chronic inflammation marker is 
not specific of cardiac injury, since it has been involved in 
various organs fibrotic degeneration processes13 and even 
with ageing14 and tumor mediation15, the healthy heart ex-
presses minimum amounts of Gal-3, which increases as HF 
progresses.16
Our finding that patients with renal impairment have higher 
Gal-3 levels is corroborated by various trials.17, 18, 19, 20
We are able to verify the assumption of numerous authors that 
patients with higher levels of Gal-3 have, also, higher levels 
of brain natriuretic peptides.6, 17, 18, 19, 20
In our research no correlation was identified between Gal-3 
serum determinations and gender or LVEF, findings reminiscent 
of those of a sub analysis of the HF-ACTION study.21
Concerning NYHA functional class no correlation with Gal-3 
was identified by us, likewise the sub analysis of the DEAL-
HF and PRIDE HF trials.11, 17, 18, 22
Meijers WC et al. observed an association between elevat-
ed plasma Gal-3 and short-term readmission in HF23, which 
supports our results.
The role of Gal-3 as a predictor of short-term mortality is 
backed by the PRIDE sub analysis.11
The DEAL-HF trial enrolled NYHA functional class III and IV 
patients, a study population similar to ours, and recognized 
that Gal-3 was a reliable mortality predictor.18
A recent metanalysis also verified a correlation between Gal-
3 and mortality.24
The sub analysis of the COACH trial, with a follow-up dura-
tion similar to ours, verified that Gal-3 was a predictor of the 
composite of all-cause mortality and HF hospitalization and 
that a multimarker strategy with NT-proBNP perfected risk 
stratification, which validates our findings.6
We emphasize that mortality risk related to Gal-3 decreased 














days post-discharge implicate a maximum risk period that 
declines over time.
The pathophysiological role of ST2 in HF, is based in the car-
dioprotective effect of the interaction of its transmembrane 
receptor (ST2L) and its ligand, IL-33, a cytokine released in 
response to cardiomyocyte strain.25
The duality IL-33/ST2L, participates in several inflammatory 
conditions, beyond cardiac distress, but although unspecific, 
it is expressed in cardiac fibroblasts and cardiomyocytes due 
to myocardial damage. 25
Its beneficial cardiac effect derives from the counterbalance 
of cardiac apoptosis, myocardial fibrosis, cardiomyocyte hy-
pertrophy, and ultimately, by increasing myocardial function. 25
This advantageous effect is abrogated by the soluble isoform 
(sST2), which acts as a decoy receptor, by binding to IL-33 
and blocking its signaling. 25
Thus, the rationale of using sST2 as HF biomarker relies on 
the fact that its levels are increased in cardiomyocyte dam-
age, namely remodeling, fibrosis and hypertrophy. 25
Likewise several authors, we identified that ST2 levels vary 
inversely with the GFR.7, 26, 27
As for age, as acknowledged by Rehman S et al.,7 no consis-
tent correlation was identified in our investigation. 
Our finding that heightened levels of ST2 predicted end of 
follow-up mortality is confirmed by the aforementioned study 
(the AUC ROC for mortality at 1 year was 0.71).7
This conclusion is, also, sustained by the PRIDE trial, since a 
trend towards high concentrations of ST2 and one year-mor-
tality was acknowledged.28 
Relevantly, the mutual quantification of ST2 and NT-proBNP 
improved risk stratification,28 as verified in our research.
Similarly to Wang CH et al,29 the combination of fibrosis bio-
markers identified patients with higher risk of mortality.
As expected end of follow-up mortality risk linked to ST2 and 
Gal-3 simultaneous quantification, was greatest in the HFrEF, 
which is a more vulnerable subgroup, and lowest in the HFpEF. 
The weight of evidence suggests that Gal-3 and ST2 can be 
useful tools to detect and stratify high risk HF patients. 
Given their role in cardiac remodeling and consequently in the 
HF inexorable continuum, one must question if in a near future 
they will ascend as new cardiovascular therapeutic targets.
Due to the small sample size we did not perform multivariable 
analysis. Moreover, our research was a single-center study 
which may limit the extrapolation of our acknowledgments. 
Nevertheless, this study reports data from a real-world clin-
ical background and the results are consistent with previ-
ously published large scale studies, therefore supporting the 
validity of our findings.
CONCLUSIONS
Elevated Gal-3 concentrations correlated with short-term 
rehospitalization, short-term mortality and end of follow-up 
mortality; whereas ST2 prognosticated end of follow-up 
mortality. 
These results corroborate the assumption that promising 
novel biomarkers Gal-3 and ST2 could be valuable for HF 
risk stratification.
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aTable 2. Crude survival analysis for Gal-3 ≥10.97 ng/mL
Biomarker Early rehospitalization Early mortality End of follow-up mortality















p-value: * - < 0.05; ** - < 0.01; *** - < 0.001. NC- not calculable due to small number of  cases
Table 3. End of follow-up mortality crude survival analysis for ST2 ≥24.78 pg/mL
Biomarker
End of follow-up mortality
HR (95% CI)
ST2 ≥24.78 ng/L (population study) 4.846 (1.396-16.825)**
ST2 ≥24.78 ng/L NT-proBNP ≥21336 ng/L (population study) 5.953 (1.683-21.055)**
ST2 ≥24.78 ng/L Gal-3 ≥9.99 ng/mL (population study) 6.209 (2.393-16.114)***
ST2 ≥24.78 pg/m and Gal-3 ≥9.99 ng/mL
(HFpEF subgroup)
5.2 (1.223-22.187)**
ST2 ≥24.78 ng/L Gal-3 ≥9.99 ng/mL (HFrEF subgroup) 15.782 (1.593-156.322) **
p-value: * - < 0.05; ** - < 0.01; *** - < 0.001
HFpEF: Heart Failure with Preserved Ejection Fraction, HFrEF: Heart Failure with Reduced Ejection Fraction.
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a We highlight that a multi-marker strategy added information, 
as a synergism between myocardial fibrosis biomarkers and 
NT-proBNP was observed.
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